InvestSMART

Burgundy Diamond Mines Limited (ASX: BDM) - Announcements

- Current share price for BDM : $0.017

ASX company news and announcements for Burgundy Diamond Mines Limited (BDM) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Burgundy Diamond Mines Limited (BDM) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Burgundy Diamond Mines Limited (BDM), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Burgundy Diamond Mines Limited (BDM)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$24 BioDiem signs seed development research agreement with RMIT. 19 Jul 2012 10:15AM $0.061 $0.017 fallen by 72.13%
$24 BioDiem secures rights to novel Hepatitis technology 26 Jun 2012 1:15PM $0.060 $0.017 fallen by 71.67%
$24 BioDiem signs Dengue Fever agreement with ANU 25 Jun 2012 12:40PM $0.060 $0.017 fallen by 71.67%
$24 ANU to grant BioDiem exclusive license for novel technology 6 Jun 2012 10:25AM $0.077 $0.017 fallen by 77.92%
$24 BioDiem partners with Foundation Fighting Blindness 30 May 2012 10:30AM $0.077 $0.017 fallen by 77.92%
$24 BioDiem LAIV to be tested in French proprietary cell line 9 May 2012 10:10AM $0.083 $0.017 fallen by 79.52%
$24 BDM-I patent position strengthened with new US patent 3 May 2012 10:26AM $0.083 $0.017 fallen by 79.52%
$24 Appendix 4C - quarterly 30 Apr 2012 2:04PM $0.070 $0.017 fallen by 75.71%
$24 April 2012 Shareholder Update 23 Apr 2012 10:07AM $0.090 $0.017 fallen by 81.11%
$24 Half Year Report and Accounts 29 Feb 2012 9:49AM $0.085 $0.017 fallen by 80%
$24 BioDiem Licenses LAIV Technology to Changchun BCHT Biotechno 9 Feb 2012 2:22PM $0.075 $0.017 fallen by 77.33%
$24 BioDiem Ltd acquires Savine Therapeutics Pty Ltd 14 Dec 2011 12:46PM $0.084 $0.017 fallen by 79.76%
$24 Preliminary Final Report 26 Aug 2011 9:33AM $0.085 $0.017 fallen by 80%
$24 BioDiem Replaces Nobilon as Licensor of LAIV to WHO 1 Aug 2011 10:01AM $0.100 $0.017 fallen by 83%
$24 BioDiem Licenses LAIV Technology to Serum Institute of India 1 Aug 2011 10:01AM $0.100 $0.017 fallen by 83%
$24 BioDiem Regains Rights to LAIV Technology 1 Aug 2011 9:54AM $0.100 $0.017 fallen by 83%
$24 Appendix 4C - quarterly 28 Jul 2011 12:30PM $0.090 $0.017 fallen by 81.11%
$24 Appendix 4C - quarterly 29 Apr 2011 3:57PM $0.160 $0.017 fallen by 89.38%
$24 Half Yearly Report and Accounts 28 Feb 2011 1:28PM $0.130 $0.017 fallen by 86.92%
$24 Appendix 4C - quarterly 28 Jan 2011 9:33AM $0.160 $0.017 fallen by 89.38%
$24 BioDiem Receives US$0.25m Royalties on Sales from NASOVAC 16 Dec 2010 12:12PM $0.130 $0.017 fallen by 86.92%
$24 US and China Patents Granted for BioDiem`s BDM-I 1 Dec 2010 4:04PM n/a $0.017 n/a
$24 Appendix 4C - quarterly 29 Oct 2010 11:06AM $0.130 $0.017 fallen by 86.92%
$24 Merck - Schering-Plough Update - Nobilon facility 11 Oct 2010 9:59AM n/a $0.017 n/a
$24 BioDiem Places $1 million of Rights Issue Shortfall 21 Sep 2010 4:57PM n/a $0.017 n/a

351 - 375 of 458 results

Page 15 of 19

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.